Cytokinetics, Inc.

CytoKinetics

Overview

CytoKinetics is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing novel muscle activators and inhibitors for the treatment of diseases of impaired muscle function. The company's vision is "empowering muscle, empowering lives" with a focus on cardiac and skeletal muscle disorders[@cytokinetics].

Pipeline Overview

| Program | Target/Mechanism | Indication | Stage | Status |
|---------|-----------------|------------|-------|--------|
| Aficamten (CK-037825) | Cardiac myosin inhibitor | Hypertrophic cardiomyopathy | Approved | MYQORZO™ |
| Reldesomstat (CK-2127107) | Fast skeletal muscle troponin inhibitor | ALS | Phase 3 | Clinical |
| CK-089 | Fast skeletal muscle troponin activator | Neuromuscular | Phase 1 | Active |

Corporate History

• 1998: Operations began in South San Francisco
• 2004: Completed initial public offering (NASDAQ: CYTK)
• 2008: Strategic realignment focused on muscle biology
• 2018: Began Phase 1 study of cardiac myosin inhibitor
• 2023: Announced results from SEQUOIA-HCM Phase 3 trial
• 2024: FDA accepted New Drug Application for aficamten
• 2025: Received first FDA approval for MYQORZO™ (aficamten) for obstructive HCM

Strategic Partnerships

CytoKinetics has established strategic partnerships with major pharmaceutical companies:

• Astellas Pharma: Collaboration on fast skeletal muscle activators
• Amgen: Option agreement for cardiac myosin inhibitor program
• Royalty Pharma: Royalty financing arrangement

...

CytoKinetics

Overview

CytoKinetics is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing novel muscle activators and inhibitors for the treatment of diseases of impaired muscle function. The company's vision is "empowering muscle, empowering lives" with a focus on cardiac and skeletal muscle disorders[@cytokinetics].

Pipeline Overview

| Program | Target/Mechanism | Indication | Stage | Status |
|---------|-----------------|------------|-------|--------|
| Aficamten (CK-037825) | Cardiac myosin inhibitor | Hypertrophic cardiomyopathy | Approved | MYQORZO™ |
| Reldesomstat (CK-2127107) | Fast skeletal muscle troponin inhibitor | ALS | Phase 3 | Clinical |
| CK-089 | Fast skeletal muscle troponin activator | Neuromuscular | Phase 1 | Active |

Corporate History

• 1998: Operations began in South San Francisco
• 2004: Completed initial public offering (NASDAQ: CYTK)
• 2008: Strategic realignment focused on muscle biology
• 2018: Began Phase 1 study of cardiac myosin inhibitor
• 2023: Announced results from SEQUOIA-HCM Phase 3 trial
• 2024: FDA accepted New Drug Application for aficamten
• 2025: Received first FDA approval for MYQORZO™ (aficamten) for obstructive HCM

Strategic Partnerships

CytoKinetics has established strategic partnerships with major pharmaceutical companies:

• Astellas Pharma: Collaboration on fast skeletal muscle activators
• Amgen: Option agreement for cardiac myosin inhibitor program
• Royalty Pharma: Royalty financing arrangement

Financial Information

Stock Ticker: CYTK (NASDAQ)

The company has maintained a strong financial position with ongoing clinical trials and recent FDA approval providing commercial revenue potential.

Neurological Relevance

While primarily focused on cardiac and skeletal muscle disorders, CytoKinetics has relevance to neurodegenerative disease research through:

ALS Program (Reldesomstat)

The company's Phase 3 program in amyotrophic lateral sclerosis (ALS) targets muscle function:

• Fast skeletal muscle troponin inhibitor
• Aims to improve muscle strength and function in ALS patients
• Addresses the muscle weakness component of ALS pathology

Neurodegeneration" style="color:#e0e0e0;margin:1.2rem 0 0.5rem;font-size:1rem;font-weight:600;border-bottom:1px solid rgba(255,255,255,0.08);padding-bottom:0.3rem">Connection to Neurodegeneration

Muscle dysfunction is a significant component of several neurodegenerative diseases:

• [ALS](/diseases/amyotrophic-lateral-sclerosis) affects motor [neurons](/entities/neurons) leading to muscle weakness
• Age-related muscle decline (sarcopenia) compounds neurodegenerative conditions
• Cardiac muscle involvement in some neurodegenerative diseases

Cross-References

• [ALS Pipeline Companies](/companies/als-pipeline-companies)
• [Amylyx Pharmaceuticals](/companies/amylyx)
• [Biogen](/companies/biogen)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Clinical Trial Pipeline

ALS Programs

Reldesat (CK-2127107)
A fast skeletal muscle troponin activator (FSTA) designed to improve muscle function in ALS[@cytokinetics].

• [Phase II**: Demonstrated increased muscle force in patients](/institutions/usc)
• Phase III: RESILIENT trial enrolling globally

CK-601: Next-generation FSTA with improved pharmacokinetics

Heart Failure Programs

Omecamtiv mecarbil (CK-037)
Cardiac myosin activator for heart failure with reduced ejection fraction (HFrEF)[@myqorzo2025].

• [Phase III GALACTIC-HF**: Positive results, filed for approval](/proteins/app)
• [Mechanism**: Increases sarcomere contraction duration without increasing oxygen consumption](/genes/ar)

Spinal Muscular Atrophy

CK-2127107: Being studied in pediatric SMA patients

Corporate Partnerships

• Amgen: Strategic partnership for heart failure program (ended 2023)
• AstraZeneca: Co-development of ALS programs
• National Institutes of Health: NIH Blueprint Neurotherapeutics network

Financial Overview

• Founded: 1997
• Headquarters: South San Francisco, California
• NASDAQ: CYTK
• Market Cap: ~.2B (as of 2026)
• Revenue: Primarily from partnerships and grants

Research Focus Areas

Muscle biology: Skeletal and cardiac muscle activators

Cytoskeletal dynamics: Novel mechanisms for muscle function

Neuromuscular disorders: ALS, SMA, myasthenia gravis

Heart failure: Novelotropin class compounds

[@cytokinetics]: [Reldesat ALS Program](https://www.cytokinetics.com/). Cytokinetics.
[@myqorzo2025]: [Omecamtiv Mecarbil](https://www.cytokinetics.com/). Cytokinetics.

References

Unknown, CytoKinetics Corporate Website (n.d.)

Unknown, MYQORZO FDA Approval - PR Newswire 2025 (2025)

Unknown, FORTITUDE-ALS Trial - ClinicalTrials.gov (n.d.)